Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR75B | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7555.091 | 0.8382 | 0.7916 | 1.6040 | |
| 184B5 | NM | Basal | Etoposide | TOP2 | TOP | 66.7 | uM | 5897.074 | 0.4955 | 0.1567 | 1.2824 | |
| SUM229PE | TNBC | - | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14807.203 | 0.0227 | -0.7798 | 1.7148 | |
| HCC2185 | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7464.084 | 0.9932 | 0.9834 | 0.8152 | |
| SK-BR-3 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7526.091 | 0.3046 | -0.0181 | 1.6709 | |
| MDA-MB-175-VII | HR+ | Luminal | AS-252424 | PI3K | PI3K | 66.7 | uM | 12126.158 | 0.7448 | 0.2233 | 0.5992 | |
| 600MPE | HR+ | Luminal | Etoposide | TOP2 | TOP | 66.7 | uM | 5899.074 | 0.4800 | -0.1265 | 0.8860 | |
| HCC2185 | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7463.084 | 0.9597 | 0.8941 | 0.7560 | |
| HCC3153 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7466.085 | 0.9838 | 0.9627 | 0.8684 | |
| BT-549 | TNBC | Basal B | MG-132 | Proteasome | Proteasome | 66.7 | uM | 14200.189 | 1.0697 | 1.0413 | 3.2969 | |
| HCC70 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7470.085 | 0.8466 | 0.6898 | 0.9880 | |
| 600MPE | HR+ | Luminal | Etoposide | TOP2 | TOP | 66.7 | uM | 5898.074 | 0.5859 | -0.0547 | 0.7134 | |
| HCC1569 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14727.203 | 0.1300 | -0.3648 | 1.7785 | |
| HCC1954 | HER2amp | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7457.084 | 0.6216 | 0.5472 | 1.8520 | |
| CAMA-1 | HR+ | Luminal | MG-132 | Proteasome | Proteasome | 66.7 | uM | 12070.145 | 0.0096 | -0.9737 | 1.0737 | |
| SUM1315MO2 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 66.7 | uM | 12428.167 | 0.7862 | 0.5788 | 1.0169 | |
| AU565 | HER2amp | Luminal | Etoposide | TOP2 | TOP | 66.7 | uM | 5900.074 | 0.0362 | -0.4929 | 2.4189 | |
| HCC70 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 66.7 | uM | 12400.167 | 1.0208 | 1.0329 | 1.2627 | |
| HCC202 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7458.084 | 0.8062 | 0.3662 | 0.5653 | |
| SUM229PE | TNBC | - | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15338.203 | 0.0261 | -0.7052 | 1.9034 | |
| HCC1937 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7452.084 | 1.0228 | 1.0270 | 1.6800 | |
| HCC1937 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7453.084 | 0.9717 | 0.9636 | 1.5592 | |
| HCC1806 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7450.084 | 0.9422 | 0.9498 | 2.3432 | |
| HCC1569 | HER2amp | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7449.084 | 0.9294 | 0.9327 | 2.1410 | |
| HCC1806 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7451.085 | 0.3029 | 0.1463 | 2.1458 |